ArticleViruses2021
Serological Cross-Reactions between Expressed VP2 Proteins from Different Bluetongue Virus Serotypes.
Article in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 19 citations in OpenAlex.
- Bluetongue virus: current perspectives on characterisation and the need to formalise nomenclature in an era of rapidly evolving technology.The Journal of general virology · 2026Review
- The changing landscape of bluetongue in northern Europe.Journal of medical entomology · 2026Review
- A Molecular and Structural Perspective on Bluetongue Virus Entry and Assembly.Pathogens (Basel, Switzerland) · 2026Review
- Exceptional Bluetongue Epidemic Caused by Co-Circulation of Several Serotypes in Spain in 2024.Microorganisms · 2026Article
- Detection and serotyping of bluetongue viruses in Khyber Pakhtunkhwa Province, Pakistan.Tropical animal health and production · 2026Article
- Rapid Quantification of Bluetongue Virus-Neutralizing Antibodies Using Bioluminescent Reporter-Expressing Viruses.Vaccines · 2025Article
- Bluetongue in ruminants: Global epidemiology, pathogenesis, and advances in diagnostic and control strategies within a One Health framework.Veterinary world · 2025Review
- Biomimetic Apatite Nanoparticles and Microcrystalline Tyrosine as Biocompatible Vaccine Adjuvants: Performance in a Bluetongue Virus Sheep Model.ACS applied materials & interfaces · 2025Article
- Bluetongue's New Frontier-Are Dogs at Risk?Veterinary sciences · 2025Review
- Impact of BTV-3 Circulation in Belgium in 2024 and Current Knowledge Gaps Hindering an Evidence-Based Control Program.Viruses · 2025Article
- Emerging Bluetongue Virus Serotype 4 in the Balearic Islands, Spain (2021): Outbreak Investigations and Experimental Infection in Sheep.Microorganisms · 2025Article
- The MVA-VP2-NS1-2A-NS2-Nt vaccine candidate provides heterologous protection in sheep against bluetongue virus.Frontiers in immunology · 2025Article
- High seroprevalence and age-associated dynamics of bluetongue and epizootic hemorrhagic disease viruses in North American bison (Frontiers in veterinary science · 2025Article
- Impact of VP2 structure on antigenicity: comparison of BTV1 and the highly virulent BTV8 serotype.Journal of virology · 2024Article
- Co-expression of VP2, NS1 and NS2-Nt proteins by an MVA viral vector induces complete protection against bluetongue virus.Frontiers in immunology · 2024Article
- Epizootic Hemorrhagic Disease Virus: Current Knowledge and Emerging Perspectives.Microorganisms · 2023Review
- Increased Clinical Signs and Mortality in IFNARPathogens (Basel, Switzerland) · 2023Article
- Vaccination as a Strategy to Prevent Bluetongue Virus Vertical Transmission.Pathogens (Basel, Switzerland) · 2021Review
- Clinical presentation, medical management, and outcomes in 35 hospitalized sheep diagnosed with bluetongue virus disease.Journal of veterinary internal medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 3 countries.
Funding
Abstract
Bluetongue (BT) is a severe and economically important disease of ruminants that is widely distributed around the world, caused by the bluetongue virus (BTV). More than 28 different BTV serotypes have been identified in serum neutralisation tests (SNT), which, along with geographic variants (topotypes) within each serotype, reflect differences in BTV outer-capsid protein VP2. VP2 is the primary target for neutralising antibodies, although the basis for cross-reactions and serological variations between and within BTV serotypes is poorly understood. Recombinant BTV VP2 proteins (rVP2) were expressed in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.